Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1978 1
1980 3
1981 1
1982 1
1983 1
1984 4
1985 2
1986 4
1987 1
1988 1
1989 2
1990 1
1992 2
1993 1
1995 2
1996 3
1997 2
1998 1
1999 1
2001 2
2002 4
2003 3
2004 2
2005 6
2006 4
2007 2
2008 3
2009 4
2010 3
2011 3
2012 4
2013 2
2014 5
2015 10
2016 7
2017 5
2018 9
2019 8
2020 12
2021 11
2022 19
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
Gazzah A, Bedard PL, Hierro C, Kang YK, Abdul Razak A, Ryu MH, Demers B, Fagniez N, Henry C, Hospitel M, Soria JC, Tabernero J. Gazzah A, et al. Ann Oncol. 2022 Apr;33(4):416-425. doi: 10.1016/j.annonc.2021.12.012. Epub 2022 Jan 10. Ann Oncol. 2022. PMID: 35026412 Free article. Clinical Trial.
RESULTS: Thirty-one patients received tusamitamab ravtansine (range 5-150 mg/m(2)). The DLT population comprised 28 patients; DLTs (reversible grade 3 microcystic keratopathy) occurred in three of eight patients treated with tusamitamab ravtansine 120 mg/m(2) and in …
RESULTS: Thirty-one patients received tusamitamab ravtansine (range 5-150 mg/m(2)). The DLT population comprised 28 patients; DLTs (r …
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms.
Son K, Jamil R, Chowdhury A, Mukherjee M, Venegas C, Miyasaki K, Zhang K, Patel Z, Salter B, Yuen ACY, Lau KS, Cowbrough B, Radford K, Huang C, Kjarsgaard M, Dvorkin-Gheva A, Smith J, Li QZ, Waserman S, Ryerson CJ, Nair P, Ho T, Balakrishnan N, Nazy I, Bowdish DME, Svenningsen S, Carlsten C, Mukherjee M. Son K, et al. Eur Respir J. 2023 Jan 12;61(1):2200970. doi: 10.1183/13993003.00970-2022. Print 2023 Jan. Eur Respir J. 2023. PMID: 36137590 Free PMC article.
We investigated whether anti-nuclear/extractable-nuclear antibodies (ANAs/ENAs) were present up to a year after infection, and if they were associated with the development of clinically relevant post-acute sequalae of COVID-19 (PASC) symptoms. METHODS: A rapid-assessment l …
We investigated whether anti-nuclear/extractable-nuclear antibodies (ANAs/ENAs) were present up to a year after infection, and if the …
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM. Armand P, et al. J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584546 Free PMC article. Clinical Trial.
Abstracts from the 3rd International Genomic Medicine Conference (3rd IGMC 2015) : Jeddah, Kingdom of Saudi Arabia. 30 November - 3 December 2015.
Shay JW, Homma N, Zhou R, Naseer MI, Chaudhary AG, Al-Qahtani M, Hirokawa N, Goudarzi M, Fornace AJ Jr, Baeesa S, Hussain D, Bangash M, Alghamdi F, Schulten HJ, Carracedo A, Khan I, Qashqari H, Madkhali N, Saka M, Saini KS, Jamal A, Al-Maghrabi J, Abuzenadah A, Chaudhary A, Al Qahtani M, Damanhouri G, Alkhatabi H, Goodeve A, Crookes L, Niksic N, Beauchamp N, Abuzenadah AM, Vaught J, Budowle B, Assidi M, Buhmeida A, Al-Maghrabi J, Buhmeida A, Assidi M, Merdad L, Kumar S, Miura S, Gomez K, Carracedo A, Rasool M, Rebai A, Karim S, Eldin HFN, Abusamra H, Alhathli EM, Salem N, Al-Qahtani MH, Kumar S, Faheem H, Agarwa A, Nieschlag E, Wistuba J, Damm OS, Beg MA, Abdel-Meguid TA, Mosli HA, Bajouh OS, Abuzenadah AM, Al-Qahtani MH, Coskun S, Abu-Elmagd M, Buhmeida A, Dallol A, Al-Maghrabi J, Hakamy S, Al-Qahtani W, Al-Harbi A, Hussain S, Assidi M, Al-Qahtani M, Abuzenadah A, Ozkosem B, DuBois R, Messaoudi SS, Dandana MT, Mahjoub T, Almawi WY, Abdalla S, Al-Aama MN, Elzawahry A, Takahashi T, Mimaki S, Furukawa E, Nakatsuka R, Kurosaka I, Nishigaki T, Nakamura H, Serada S, Naka T, Hirota S, Shibata T, Tsuchihara K, Nishida T, Kato M, Mehmood S, Ashraf NM, Asif A, Bilal M, Mehmood MS, Hussain … See abstract for full author list ➔ Shay JW, et al. BMC Genomics. 2016 Jul 20;17 Suppl 6(Suppl 6):487. doi: 10.1186/s12864-016-2858-0. BMC Genomics. 2016. PMID: 27454254 Free PMC article.
Ead, Ola M Ead, Mona Mekkawy, Innas Mazen, Mona El-Ruby P24 Analysis of binding properties of angiotensin-converting enzyme 2 through in silico method S. ...Shehab P29 Altered expression of CD200R1 on dendritic cells of patients with inflammatory bowel diseases: in …
Ead, Ola M Ead, Mona Mekkawy, Innas Mazen, Mona El-Ruby P24 Analysis of binding properties of angiotensin-converting enzyme 2 through …
Structure-dependent high-TC ferromagnetism in Mn-doped GeSe.
Li D, Zhang X, He W, Lei L, Peng Y, Xiang G. Li D, et al. Nanoscale. 2022 Sep 22;14(36):13343-13351. doi: 10.1039/d2nr02955c. Nanoscale. 2022. PMID: 36069243
All the samples exhibit FM, and their T(C) and saturation magnetization (M(S)) are correlated to their structures. Notably, GeMnSe SC-NCs show a record high T(C) of 309 K and a record strong magnetic moment of 4.37mu(B)/Mn compared to all the previously-reported IV- …
All the samples exhibit FM, and their T(C) and saturation magnetization (M(S)) are correlated to their structures. Notably, Ge …
Luminescent quantum dots: Synthesis, optical properties, bioimaging and toxicity.
Sobhanan J, Rival JV, Anas A, Sidharth Shibu E, Takano Y, Biju V. Sobhanan J, et al. Adv Drug Deliv Rev. 2023 Jun;197:114830. doi: 10.1016/j.addr.2023.114830. Epub 2023 Apr 20. Adv Drug Deliv Rev. 2023. PMID: 37086917 Review.
Surface modified and bioconjugated core-only and core-shell QDs of metal chalcogenides (MX; M = Cd/Pb/Hg/Ag, and X = S/Se/Te,), binary metal chalcogenides (MInX(2); M = Cu/Ag, and X = S/Se/Te), indium compounds (InAs and InP), metal NPs (Ag, Au, and Pt …
Surface modified and bioconjugated core-only and core-shell QDs of metal chalcogenides (MX; M = Cd/Pb/Hg/Ag, and X = S/Se/Te,) …
Emerging technologies in autoantibody testing for rheumatic diseases.
Olsen NJ, Choi MY, Fritzler MJ. Olsen NJ, et al. Arthritis Res Ther. 2017 Jul 24;19(1):172. doi: 10.1186/s13075-017-1380-3. Arthritis Res Ther. 2017. PMID: 28738887 Free PMC article. Review.
Testing for the presence of antinuclear antibodies (ANAs) is a key step in the diagnosis of systemic lupus erythematosus (SLE) and other systemic autoimmune rheumatic diseases (SARD). The standard slide-based indirect immunofluorescence (IIF) test is widely used, but is li …
Testing for the presence of antinuclear antibodies (ANAs) is a key step in the diagnosis of systemic lupus erythematosus (SLE) and ot …
TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.
Erazo T, Evans CM, Zakheim D, Chu KL, Refermat AY, Asgari Z, Yang X, Da Silva Ferreira M, Mehta S, Russo MV, Knezevic A, Zhang XP, Chen Z, Fennell M, Garippa R, Seshan V, de Stanchina E, Barbash O, Batlevi CL, Leslie CS, Melnick AM, Younes A, Kharas MG. Erazo T, et al. Nat Commun. 2022 Sep 27;13(1):5676. doi: 10.1038/s41467-022-33137-8. Nat Commun. 2022. PMID: 36167829 Free PMC article.
Airway autoantibodies are determinants of asthma severity.
Salter B, Zhao N, Son K, Tan NS, Dvorkin-Gheva A, Radford K, LaVigne N, Huang C, Kjarsgaard M, Li QZ, Tselios K, Lim HF, Khalidi N, Nair P, Mukherjee M. Salter B, et al. Eur Respir J. 2022 Dec 1;60(6):2200442. doi: 10.1183/13993003.00442-2022. Print 2022 Dec. Eur Respir J. 2022. PMID: 35777765
Auto-IgG antibodies directed against granule proteins such as eosinophil peroxidase (EPX), macrophage scavenger receptor with collagenous structure (MARCO) and nuclear/extranuclear antigens (antinuclear antibodies (ANAs)) have been reported. Our objective was to describe t …
Auto-IgG antibodies directed against granule proteins such as eosinophil peroxidase (EPX), macrophage scavenger receptor with collagenous st …
170 results